MET and glioblastoma: On the other hand, the phase II study GO27819 aimed to assess the efficacy of the monovalent MET inhibitor onartuzumab in combination with bevacizumab (Ona+Bev) versus placebo plus bevacizumab (Pla+Bev) for recurrent glioblastoma, considering the reported aberrant expression of c-MET in glioblastoma.